Your search for hypertension returned 1974 results

The Company acquired exclusive rights to commercialize the product from Tris Pharma in February 2021.

The strength of the scientific evidence supporting the relationship will be disclosed as “supportive but inconclusive” to avoid misleading consumers.

The researchers examined data from the National Health and Nutrition Examination Survey.

Yutrepia is an inhaled dry powder formulation of tresprostinil delivered through a palm-sized device.

Bigger drop in systolic BP but less intensification sustainability seen with addition of new med versus maximizing dose of current med

Reduction in systolic blood pressure greater at week 12 with fixed-dose quadruple quarter-dose combo versus standard-dose monotherapy

AER-901 is an investigational drug-device combination therapy that consists of a nebulized formulation of imatinib and the Fox device, a breath-actuated smart nebulizer.

The approval was based on data from a single sequence cross-over phase 3 study that evaluated the safety, tolerability and pharmacokinetics of temporarily switching between the tablet and IV formulation.

Currently, ACE inhibitors and ARBs are both recommended as first-line therapies for the treatment of hypertension according to US and European guidelines.

Screening for hypertension with office blood pressure measurement recommended for adults aged 18 years and older